Contineum Therapeutics (CTNM) Current Assets: 2023-2025
Historic Current Assets for Contineum Therapeutics (CTNM) over the last 2 years, with Sep 2025 value amounting to $184.9 million.
- Contineum Therapeutics' Current Assets fell 14.04% to $184.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $184.9 million, marking a year-over-year decrease of 14.04%. This contributed to the annual value of $206.4 million for FY2024, which is 61.61% up from last year.
- According to the latest figures from Q3 2025, Contineum Therapeutics' Current Assets is $184.9 million, which was up 4.57% from $176.8 million recorded in Q2 2025.
- Contineum Therapeutics' 5-year Current Assets high stood at $220.3 million for Q2 2024, and its period low was $119.7 million during Q1 2024.
- Over the past 3 years, Contineum Therapeutics' median Current Assets value was $188.5 million (recorded in 2025), while the average stood at $180.4 million.
- As far as peak fluctuations go, Contineum Therapeutics' Current Assets soared by 61.61% in 2024, and later dropped by 19.74% in 2025.
- Quarterly analysis of 3 years shows Contineum Therapeutics' Current Assets stood at $127.7 million in 2023, then spiked by 61.61% to $206.4 million in 2024, then dropped by 14.04% to $184.9 million in 2025.
- Its Current Assets was $184.9 million in Q3 2025, compared to $176.8 million in Q2 2025 and $192.1 million in Q1 2025.